ArticleJournal for immunotherapy of cancer2023

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.

Philip Clingan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.